Immuneering Corp (IMRX)
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Immuneering Corporation
NASDAQ:IMRXHealthcare · Biotechnology
-6.84%$3.75
AH$3.69-1.47%vs close
Mkt Cap$242.54M
Float49.43M
O/S64.76M
Vol
$ Vol
RVOL
Inst Own53.3%
SI33.0%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$56.02M
Total Assets$231.99M
Free Cash Flow-$45.49M
Debt & Equity
Debt 2%
Equity 98%
Total Debt$3.82M
Total Equity$218.48M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in IMRX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$231.99M
Liabilities$13.5M
Accounts Receivable$0
Accounts Payable$1.54M
Inventory$0
PP&E (Net)$4.26M
Goodwill$6.69M
Intangible Assets$321K
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $317K | $2.08M | $2.31M | $1.92M |
| YoY Growth | - | - | - | -84.8% | -10.0% | 20.4% | - |
| Cost of Revenue | $699K | $0 | $0 | $158K | $1.15M | $1.28M | $1.22M |
| Gross Profit | -$699K | $0 | $0 | $159K | $927K | $1.03M | $697K |
| Gross Margin | - | - | - | 50.1% | 44.6% | 44.6% | 36.3% |
| Research and Development | $42.05M | $47.96M | $41.62M | $36.27M | $26.54M | $15M | $4.28M |
| Selling, General, and Administrative | $17.3M | $16.08M | $16.76M | $15.61M | $8.27M | $3.11M | $2.71M |
| Other | -$670K | $29K | $29K | $30K | $0 | $0 | $0 |
| Total Operating Expenses | $58.68M | $64.07M | $58.41M | $51.9M | $34.81M | $18.11M | $6.99M |
| Operating Income (EBIT) | -$59.38M | -$64.07M | -$58.41M | -$51.74M | -$33.89M | -$17.08M | -$6.29M |
| Operating Margin | - | - | - | -16325.8% | -1629.2% | -739.0% | -327.7% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $351K |
| Interest Income | $3.04M | $2.59M | $3.61M | $1.01M | $170K | $43K | $58K |
| Other Income (Expense) | $3.35M | $3.03M | $4.94M | $1.23M | $43K | -$42K | -$1.42M |
| Income Before Tax (EBT) | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.84M | -$17.12M | -$7.71M |
| Income Tax Expense | $0 | $0 | $0 | $0 | -$307K | -$84K | $0 |
| Net Income | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.54M | -$17.04M | -$7.71M |
| Net Income Margin | - | - | - | -15937.3% | -1612.3% | -737.2% | -401.6% |
| Supplementary Data | |||||||
| EPS | -1.27 | -2.04 | -1.88 | -1.87 | -1.27 | -1.26 | -0.60 |
| Diluted EPS | -1.27 | -2.04 | -1.88 | -1.87 | -1.27 | -1.26 | -0.60 |
| Weighted Average OS | 44.01M | 29.98M | 28.42M | 26.39M | 26.32M | 13.51M | 13.51M |
| EBITDA | -$55.67M | -$63.69M | -$58.06M | -$51.47M | -$33.68M | -$17M | -$7.34M |
| EBITDA Margin | - | - | - | -16238.4% | -1619.5% | -735.6% | -382.4% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $128.65M | $36.14M | $59.41M | $72.64M | $74.89M | $37.09M | $13.78M |
| Short-Term Investments | $44.19M | $0 | $26.26M | $32.89M | $74.31M | $0 | $0 |
| Cash and Short-Term Investments | $172.83M | $36.14M | $85.67M | $105.52M | $149.2M | $37.09M | $13.78M |
| Accounts Receivable | $0 | $0 | $0 | $12K | $246K | $500K | $210K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.41M | $3.44M | $3.42M | $3.21M | $0 | $0 | $0 |
| Total Current Assets | $176.25M | $39.59M | $89.08M | $108.75M | $152.33M | $37.73M | $14.06M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $4.26M | $4.79M | $5.4M | $5.78M | $6.13M | $677K | $35K |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.7M | $0 | $0 |
| Intangible Assets | $321K | $350K | $380K | $409K | $439K | $0 | $0 |
| Long-Term Investments | $44.18M | $0 | $0 | $0 | $997K | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $284K | $1.3M | $1.03M | $744K | $102K | $14K | $0 |
| Total Long-Term Assets | $55.74M | $13.13M | $13.5M | $13.62M | $14.37M | $692K | $35K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $231.99M | $52.71M | $102.58M | $122.37M | $166.7M | $38.42M | $14.1M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $1.54M | $1.96M | $2.11M | $3.15M | $1.39M | $1.48M | $295K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $4.54M | $3.82M | $3.89M | $3.65M | $2.92M | $164K | $119K |
| Total Current Liabilities | $10.07M | $7.5M | $7.85M | $8.05M | $5.63M | $2.26M | $505K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $58.1M | $20.12M |
| Total Long-Term Liabilities | $3.43M | $3.82M | $4.16M | $4.46M | $5.09M | $58.65M | $20.12M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $13.5M | $11.33M | $12.01M | $12.52M | $10.72M | $60.9M | $20.63M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $65K | $31K | $29K | $26K | $26K | $5K | $5K |
| Retained Earnings | -$280.32M | -$224.3M | -$163.26M | -$109.79M | -$59.27M | -$25.74M | -$8.7M |
| Comprehensive Income & Other | $81K | $0 | -$778 | -$30K | -$49K | $0 | $0 |
| Other Stockholders' Equity | $498.74M | $265.65M | $253.81M | $219.61M | $215.23M | $3.25M | $2.16M |
| Total Equity | $218.48M | $41.39M | $90.58M | $109.85M | $155.98M | -$22.48M | -$6.53M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $231.99M | $52.71M | $102.58M | $122.37M | $166.7M | $38.42M | $14.1M |
| Supplementary Data | |||||||
| Total Debt | $3.82M | $4.16M | $4.46M | $4.84M | $5.36M | $621K | $0 |
| Net Debt | -$124.82M | -$31.98M | -$54.94M | -$67.8M | -$69.52M | -$36.47M | -$13.78M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.54M | -$17.04M | -$7.71M |
| Depreciation & Amortization | $354K | $385K | $352K | $277K | $159K | $79K | $18K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$307K | $0 | $0 |
| Stock-Based Compensation | $6.31M | $6.5M | $5.73M | $4.06M | $1.8M | $1.09M | $597K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $12K | $234K | $280K | -$290K | $614K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$401K | -$112K | -$1.11M | $1.76M | -$130K | $1.19M | $270K |
| Other Working Capital | $4.22M | -$813K | $120K | -$277K | $751K | $358K | -$447K |
| Total Working Capital Change | $3.82M | -$925K | -$975K | $1.72M | $900K | $1.25M | $437K |
| Other Non-Cash Items | $191K | $76K | -$602K | $353K | $130K | $0 | $2.22M |
| Net Cash from Operating | -$45.34M | -$55M | -$48.97M | -$44.1M | -$30.85M | -$14.62M | -$4.44M |
| Investing Activities | |||||||
| Capital Expenditures | -$142K | -$85K | -$343K | -$742K | -$61K | -$53K | -$21K |
| Acquisitions | $0 | $0 | $0 | $0 | $70K | $0 | $0 |
| Purchases of Investments | -$88.6M | -$5.41M | -$44.66M | -$50.1M | -$75.63M | $0 | $0 |
| Sales of Investments | $0 | $31.93M | $52.3M | $92.68M | $75.62M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | -$75.62M | $0 | $0 |
| Net Cash from Investing | -$88.74M | $26.43M | $7.3M | $41.83M | -$75.62M | -$53K | -$21K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | -$3.83M |
| Common Stock Issuance | $230.31M | $4.24M | $28.2M | $19K | $120.32M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$3.73M | $1.07M | $241K | $0 | -$843K | $0 | -$56K |
| Net Cash from Financing | $226.58M | $5.3M | $28.44M | $19K | $144.26M | $37.98M | $17.17M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $92.5M | -$23.26M | -$13.23M | -$2.25M | $37.8M | $23.31M | $12.71M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$45.34M | -$55M | -$48.97M | -$44.1M | -$30.85M | -$14.62M | -$4.44M |
| Capital Expenditure | -$142K | -$85K | -$343K | -$742K | -$61K | -$53K | -$21K |
| Free Cash Flow | -$45.49M | -$55.08M | -$49.31M | -$44.84M | -$30.91M | -$14.67M | -$4.46M |
| Cash at Beginning | $36.14M | $59.41M | $72.64M | $74.89M | $37.09M | $13.78M | $1.07M |
| Cash at End | $128.65M | $36.14M | $59.41M | $72.64M | $74.89M | $37.09M | $13.78M |